SGLT2 inhibitors have emerged as a key disease-modifying therapy to prevent the
progression of chronic kidney disease (CKD). These agents prevent decline in kidney …

The disclosure of proven cardiorenal benefits with certain antidiabetic agents was supposed
to herald a new era in the management of type 2 diabetes (T2D), especially for the many …

Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) were originally developed as
antidiabetic agents, with cardiovascular (CV) outcome trials demonstrating improved CV …

OBJECTIVE Randomized controlled trials have shown kidney-protective effects of sodium–
glucose cotransporter 2 (SGLT2) inhibitors, and clinical practice databases have suggested …

Diabetic kidney disease (DKD) is one of the most serious complications of both type 1
(T1DM) and type 2 diabetes mellitus (T2DM). Current guidelines recommend a personalized …

Importance Whether sodium-glucose cotransporter–2 inhibitors (SGLT-2i) are associated
with an increased risk of fractures in older adults with type 2 diabetes (T2D) outside of …

The availability of electronic health records and access to a large number of routine
measurements of serum creatinine and urinary albumin enhance the possibilities for …

Large clinical trials and real‐world studies have demonstrated that the beneficial effects of
sodium‐glucose co‐transporter 2 (SGLT2) inhibitors on renal outcomes regardless of the …

Rationale & Objective Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been found
to have many benefits for patients with type 2 diabetes. However, whether SGLT2 inhibitors …

Acute and chronic kidney disease are responsible for large healthcare costs worldwide.
During injury, kidney metabolism undergoes profound modifications in order to adapt to …